News

Even if you're not an investor like Cathie Wood, who specializes in businesses that claim to have a shot at disrupting their industries, investing in aspiring disruptors can be a great tactic to

According to data provided by S&P Global Market Intelligence, shares of DraftKings (NASDAQ: DKNG) dropped by as much as 15.7% in trading this week after the Illinois Senate approved a new budget

May has been an adventurous month for Viking (NYSE: VIK). The world's leading operator of river cruise sailings went public at $24 on May 1. On Wednesday, it delivered its first financial update as

Viking Therapeutics (NASDAQ: VKTX) stock is soaring. Two years ago, the share price hovered just above $2. Today, shares trade around $62. At Friday's prices, a paltry $100 investment in 2022 would

If you're looking at up-and-coming healthcare stocks with significant potential in the anti-obesity market, one company you've likely come across is Viking Therapeutics (NASDAQ: VKTX). Although the

The inviting market waters greeted a new cruise line operator earlier this month. Viking (NYSE: VIK) completed its initial public offering (IPO) on May 1, pricing a little more than 64 million

Things aren't so bad for investors right now. We are in a bull market even though the economy is still having some problems. However, this bull run won't last forever. There will be a slowdown

The COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller biotechs that tried to dominate this market were much less successful

Up 260% so far this year, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity thanks to its increasingly promising therapies in development to treat obesity. But as wise investors know

Novavax (NASDAQ: NVAX) stock has both soared and plummeted at times in recent years. Investors initially bet on the biotech company to be a winner in the coronavirus vaccine race, sending the stock

Vaccine maker Novavax (NASDAQ: NVAX) isn't dead in the water after all. Though the past 18 months have been tough -- and management warned investors that the business might sink soon -- Novavax

Novavax (NASDAQ: NVAX) has been a highly volatile stock in recent years, and that volatility is on full display again this month. Shares of the healthcare stock are up 200% since the start of May

Investing in clinical-stage pharmaceutical companies comes with a lot of risk, but also a lot of potential upside. When such a company delivers a successful product that passes regulatory muster --

If you'd invested $10,000 in Novavax (NASDAQ: NVAX) a year ago, you would have made a risky bet. That's because the biotech company had issued a going concern earlier this year. This warning meant

Novavax (NASDAQ: NVAX) took a turn in the investor spotlight in early May, when the vaccine specialist announced -- on the same day it unveiled its first-quarter results -- a collaboration deal with

Despite some turbulence, growth stocks have been on a bull run since the 2008 financial crisis. Groundbreaking innovations in technology and healthcare have been the primary drivers behind this

After losing more than 90% of its value from a peak back in 2021, Novavax (NASDAQ: NVAX) stock has finally taken off. The biotech soared 190% in two trading sessions after announcing a $1.2 billion

Shares of the struggling vaccine developer Novavax (NASDAQ: NVAX) bounded 98.7% higher on Friday, May 10. The market was responding to terrific news from Sanofi (NASDAQ: SNY), a global

Viking Therapeutics (NASDAQ: VKTX) has been one of the few bright spots in the healthcare sector this year. The biotech's shares have stormed higher by almost 300% year to date on the back of its

Viking Therapeutics (NASDAQ: VKTX) isn't a household name, but if its plans to commercialize a powerful anti-obesity medicine come to fruition, it may well become one. Though it has yet to

Stocks that can triple in six years aren't easy to find. Doing so requires a compound annual growth rate of 20.1%, well above the broader market's historical performance. However, it isn't

Shares of Novavax (NASDAQ: NVAX) are up 12% as of midday Friday following the release of the drugmaker's first-quarter results. It's not the report, however, driving the bulk of today's oversize

Cathie Wood can't seem to string together back-to-back years of success. The Ark Invest co-founder and CEO became a rock star among aggressive growth investors in 2020, only to see her

Image source: The Motley Fool.

MacroGenics (NASDAQ: MGNX)Q1 2024 Earnings CallMay 09, 2024, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

CorMedix (NASDAQ: CRMD)Q1 2024 Earnings CallMay 09, 2024, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com